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control. Mutations in HSPBs can lead to human disease and particularly point mutations in HSPB1 and HSPB8
are known to lead to peripheral neuropathies. Recently, a missense mutation (R7S) in yet another member of
this family, HSPB3, was found to cause an axonal motor neuropathy (distal hereditary motor neuropathy type
2C, dHMN2C).
Until now, HSPB3 protein localization and function in motoneurons (MNs) have not yet been characterized.
Therefore, we studied the endogenous HSPB3 protein distribution in the spinal cords of chicken and mouse em-
bryos and in the postnatal nervous system (central and peripheral) of chicken,mouse and human.We further in-
vestigated the impact of wild-type andmutatedHSPB3 onMN cell death via overexpressing these genes in ovo in
an avian model of MN degeneration, the limb-bud removal. Altogether, our ﬁndings represent a ﬁrst step for a
better understanding of the cellular and molecular mechanisms leading to dHMN2C.






Small heat shock proteins
Charcot-Marie-Tooth disease
Distal hereditary motor neuropathy1. Introduction
Charcot-Marie-Tooth (CMT) disease represent one of the most dif-
fuse inherited disorder of the peripheral nervous system (PNS) diseases,
with a frequency of 1 case in 2500 individuals. The demyelinating
(CMT1) and axonal (CMT2) disease forms are distinguished according
to the primarily affected cell types, the Schwann cells or the neurons, re-
spectively (Patzko and Shy, 2011). So far, mutations in N40 genes have
been identiﬁed in different forms of CMT (Tazir et al., 2014). Gene mu-
tations resulting in axonal - CMT2 - pathogenesis cause alterations inervous system; CMT, Charcot-
athy; HSPB, small heat shock
al.





. This is an open access article understructural proteins (e.g. neuroﬁlament light chain, NF-L), proteins in-
volved inmitochondrial function (e.g.mitofusin2,MFN2; ganglioside in-
duced differentiation associated protein 1, GDAP1), intracellular protein
dynamics (e.g. dynamin2, DNM2), apoptosis (e.g. small heat shock pro-
tein 1, HSPB1) or stress response (e.g. HSPB1 and small heat shock pro-
tein 8, HSPB8) (see El-Abassi et al., 2014 for a detailed review on CMT-
related mutations). In addition to this classiﬁcation, distal hereditary
motor neuropathies (dHMN) comprise a group of hereditary diseases
affecting the peripheral and slightly the sensory motor system. Their
main and shared feature is the length-dependent motor neuropathy.
Many genes have been identiﬁed to be causative for dHMN. They are in-
volved in many functional aspects of the cellular physiology, such as
protein misfolding (HSPB1, HSPB8), axonal transport (HSPB1; dynactin
subunit 1, DNCT1) and RNA metabolism (senataxin, SETX; glycyl tRNA
syntetase, GARS) (see Rossor et al., 2012 for a detailed review on
dHMN-related genes).
The human HSPB family comprises 10 members (HSPB1-HSPB10)
functioning mainly as molecular chaperones (Basha et al., 2012) and
being also involved in cell death (Acunzo et al., 2012) and cytoskeletal
dynamics (Wettstein et al., 2012). HSPBs are small ubiquitousthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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having a molecular weight ranging from 17 to 30 kDa and a length be-
tween 150 and 262 amino acids.
Recently, it was found that a heterozygous missensemutation (R7S)
in the HSPB3 gene, the smallest member of the HSPB family, causes an
early onset axonal motor neuropathywithmild or no sensory loss, clas-
siﬁed as dHMN2C (Kolb et al., 2010). This pathogenic mutation is locat-
ed in a highly conserved arginine residue at the N-terminal domain of
the HSPB3 protein (Supplementary Fig. 1a, light grey box).
Mutations in ﬁve members of the HSPB family (HSPB1, HSPB3,
HSPB4, HSPB5, and HSPB8) are linked to neurological andmuscular dis-
eases in humans. In particular, mutations on HSPB1 (Evgrafov et al.,
2004; Houlden et al., 2008) (CMT2F and dHMN2B), HSPB8 (Irobi et al.,
2010; Tang et al., 2005; Timmerman et al., 1996) (CMT2L and
dHMN2A) and HSPB3 (Kolb et al., 2010) (dHMN2C) lead to peripheral
neuropathies, but the mechanisms leading to CMT/dHMN have been
characterized in detail for the former two, only, whereas nothing is cur-
rently known about the role of HSPB3 in dHMN2C.
While HSPB3 protein distribution has not yet been investigated,
Northern blot and in situ hybridization (ISH) showed high mRNA levels
in the heart and in smooth muscle (Sugiyama et al., 2000), yet low ex-
pression in the brain cortex and other cerebral areas (Kondaurova
et al., 2011; Molyneaux et al., 2009). Still, ISH on the spinal cord of
adult mice detected a low expression of HSPB3 in motoneurons (MNs)
(Allen Spinal Cord Atlas, http://mousespinal.brain-map.org/). Addition-
ally, RT-qPCR found a low expression of HSPB3 in the cerebellum, the
spinal cord and the sciatic nerve (Kirbach and Golenhofen, 2011).
To follow up on these results we determined the localization of
HSPB3 protein in the spinal cord and nerves of chicken, mouse, and
human via optical, confocal, and transmission electron microscopy.
Our histological ﬁndings prompted us to further investigate the HSPB3
function.
To do so, we used a paradigm of lesion-induced MN cell death, the
limb-bud removal (LBR), combined with in ovo (meaning in vivo inside
the egg) electroporation (IOE) technique on chicken embryos (La
Padula et al., 2015) overexpressing the wild-type (WT) and mutated
(R7S) HSPB3 on a plasmid in MNs undergoing cell death. In parallel,
we overexpressed WT and mutated HSPB3 in embryos without LBR as
control and because this experimental condition is closer to the patho-
logical conditions in humans.
Altogether, our results indicate that HSPB3 plays an important role
in MNs survival and that its pathogenic mutation in humans probably
acquires a gain-of-function phenotype interfering with the normal ac-
tivity of the endogenous wild type HSPB3 protein.
2. Materials and methods
2.1. Testing the primary antibody against HSPB3
The polyclonal antibody against HSPB3, made using a synthetic pep-
tide based on the fragment 11–25 of the human HSPB3 protein
(Supplementary Fig., 1a dark grey box), was purchased from Sigma-
Aldrich (SAB1100972). The company reports its efﬁciency only on
human-derived samples and does not mention any other speciﬁcity
on different species. The homology between the human, avian, andmu-
rine 11–25 fragment sequence is very good (Supplementary Fig. 1b).
The fragment 11–25 of the avian HSPB3 protein is not present in any
other avianHSPB, and the same is valid for both the human and themu-
rine fragments. We therefore exclude any unspeciﬁc staining of other
HSPBs in our samples. We tested the antibody on Neuro2A cells (a mu-
rine neuroblastoma cell line) transfected or not with the plasmid carry-
ing thewild typeHSPB3 avian gene (Supplementary Fig. 1c) and stained
against HSPB3 to detect the endogenous (murine) or the overexpressed
(avian) HSPB3 protein in this in vitromodel (Supplementary Fig. 1e-1
and e-2, respectively) following standard protocols. By pre-embedding
immuno-electron microscopy (IEM) we detected HSPB3 in thecytoplasm of untransfected wild type Neuro2A cells (Supplementary
Fig. 1e-1, arrows) and HSPB3 positivity is more evident in HSPB3-
transfected Neuro2A (Supplementary Fig. 1e-2, arrows). To this positive
control, we included negative controls omitting the primary and sec-
ondary antibodies (both in IEM and in immunohistochemistry) on
chicken and human samples (Supplementary Fig. 1g-5 and g-8,
Supplementary Fig. 2f and j for immunohistochemistry negative control
stainings)where any positivitywas detectable.We also added addition-
al stainings on transversal sections of human muscle embedded in OCT
compound (TissueTek, Thermo Fisher Scientiﬁc Inc.) for cryosectioning
(muscular biopsies from patients that presented minor myopathic
changes) (10 μm thick) using the following antibodies: anti-
dystrophin (rod domain) 1 (anti-Dys1) (1:30, mouse monoconal, NCL-
DYS1, cloneDy4/6D3,Novo Castra), anti-HSPB3 (1:50, rabbit polyclonal,
SAB1100972, Sigma-Aldrich), anti-HSPB2 (1:50, mouse monoclonal, F-
9 sc514154, Santa Cruz Biotechnology) (Supplementary Fig. 2).
We also transfectedHeLa cells with our constructs and extracted the
proteins to compare theHSPB3 expression of transfected cells (express-
ing the avian HSPB3 in its wild type and mutated forms) against nega-
tive (not transfected and expressing the empty plasmid) and positive
(human muscle) controls (see further in “Protein extraction and Dot
blots”) (Supplementary Fig. 1f).
2.2. Histology and immunostainings
To study the HSPB3 protein distribution during avian development,
chicken embryos (fertilized eggs of White Leghorn, Gallus gallus
domesticus, were obtained from a local farm, Produits agricoles Haas,
Kaltenhouse, France) were collected at different time points, from em-
bryonic day (E) 3 (Hamburger and Hamilton, HH, stage 16–17) until
E14 (HH40). Embryos were removed from the eggs, decapitated, evis-
cerated and immediately ﬁxed by immersion in 4% paraformaldehyde
(PFA) in 0.1 M phosphate buffer saline (PBS) pH 7.4 overnight (ON) at
4 °C. For E9, E12 andE14 embryos, legs and ribswere removed for better
ﬁxation and embedding. Samples were washed several times in 0.1 M
PBS pH 7.4, incubated in 10% sucrose in 0.1 M PBS pH 7.4 on a rocking
plate 6 h at room temperature (RT), submerged in 30% sucrose in
0.1 M PBS pH 7.4 ON at 4 °C and ﬁnally embedded in OCT compound
(TissueTek, Thermo Fisher Scientiﬁc Inc.). Samples were stored at −
20 °C until usage. Serial transverse sections (10–30 μm) of the spinal
cord were cut with a Leica microtome (CM1520) (Leica Microsystems)
and collected on superfrost slides (Mänzel-Gläser, Thermo Fisher Scien-
tiﬁc Inc.). The mouse embryos (E13, kind gift of Dr. Vogel, University of
Freiburg) followed the same ﬁxation and embedding procedure. For
motoneuron quantiﬁcation, E6 chicken embryos followed the same em-
bedding protocol (in the dark to preserve the GFP signal) and spinal
cord transversal serial sections (10 μm) were cut from the tail over the
lumbar part of the spinal cord. Postnatal chicken (2-years-old, kind
gift of Haas farmer) and mouse (3-year-old female, kind gift of Dr.
Vogel, University of Freiburg) samples were embedded in parafﬁn fol-
lowing standard protocols. Human samples (parafﬁn embedded,
4 μm) (the spinal cord is autoptic material, from a 64-year-old man
and the sural nerve is a biopsy from a 50-year-old man) were obtained
from the Institute of Neuropathology of Freiburg (Dr. Prinz, University
of Freiburg) as well as the human muscular biopsies (gastrocnemius
muscle from a 46-year-oldman; cryosections, 10 μm). For immunoﬂuo-
rescence staining (Fig. 1 and Supplementary Fig. 1g), standard protocols
(La Padula et al., 2015)were applied and the followingprimary antibod-
ies were used: anti-Isl1/2 (39.4D5, 1:50), anti-vimentin (3CB2, 1:50),
anti-nestin (RC2, 1:50), anti-neuroﬁlament (4H6, 1:50) (all mouse
monoclonal antibodies from Developmental Studies Hybridoma Bank),
and the rabbit polyclonal anti-HSPB3 (SAB 1100972, 1:50, Sigma Al-
drich). The appropriate secondary antibodies (goat anti-mouse
AlexaFluor 568 and goat anti-rabbit AlexaFluor 488, Life Technologies)
were applied 2 h at RT. Parafﬁn-embedded samples (Fig. 2), after
deparafﬁnation and quenching of the endogenous peroxidases,
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ABC kit and revealed by diaminobenzidine (DAB) (Vectorlabs Inc.), sec-
tions were counterstained with hematoxylin, dehydrated and mounted
with non-aqueous mounting medium (Entellan, Millipore).
The cryosections frommuscle biopsies (Supplementary Fig. 2) were
left to air dry, postﬁxed 30min with 4% PFA in 0.1 M PBS, primary anti-
bodies (anti-HSPB2 1:50, Santa Cruz Biotechnologies; anti-HSPB3, 1:50,
Sigma Aldrich; anti-Dys1 1:30, Novo Castra) were diluted in 0.1 M PBS
pH 7.4 and applied 2 h at RT. Slides were rinsed with 0.1 M PBS pH 7.4
and the appropriate secondary antibodies (donkey anti-rabbit Alexa
Fluor 568 1:100; donkey anti-mouse Alexa Fluor 488 1:100, Life Tech-
nologies) diluted in 0.1 M PBS pH 7.4 were applied 1 h at RT. After rins-
ing in 0.1 M PBS pH 7.4, the slides were mounted with DAPI
Fluoromount-G (Southern Biotech), let to air dry ON at RT in the dark
and then stored at 4 °C.
Representative images of examined samples (20×) and of develop-
mental HSPB3 distribution (20, 40, and 63×)were obtainedwith a Leica
SP8 confocal microscope. For MN quantiﬁcation, images were taken
with a Nikon Axioplan 2 epiﬂuorescence microscope at 40× magniﬁca-
tion (see “Quantiﬁcation and Statistics” for details). All the images in
Supplementary Fig. 2 and Supplementary Fig. 1g have been acquired
with a Leica SP8 confocal microscope at 63× magniﬁcation.
2.3. Gene cloning
The full length Gallus gallus (Gg) domesticus HSPB3 mRNA sequence
(XM_001231557.1) was cloned in the pCIG vector (pCAGGS-IRES2-
nucEGFP; Megason and McMahon, 2002) between the XhoI and EcoRI
restriction sites. The cDNA was obtained pulling 10 spinal cords from
E7 chicken embryos following standard protocols. Brieﬂy, the spinal
cords were homogenized by pottering and the total RNA was extracted
using TriFast (PeqLab) and bromo-chloro-propane. The HSPB3 insert
was obtained by PCR ampliﬁcation (GgHSPB3-F 5′-ACCCTCGAGATGGC
AGAAGCTGTTATAAG-3′; GgHSPB3-R 5′-ACCGAATTCCTAATTAATTCC
CACCGAG-3′) and puriﬁed from a 1% agarose gel using the Nucleo
Spin Gel and PCR cleanup kit (Macherey-Nagel GmbH). The HSPB3
product was sequenced and then inserted into the pCIG vector using
standard ligation protocols.
The HSPB3-R7S insert was obtained using the gene synthesis service
provided by GenScript.
2.4. Limb-bud removal combined with in ovo electroporation (LBR/IOE)
Fertilized eggs from White Leghorn chickens (Gallus gallus
domesticus) were obtained from a local farm (Produits agricoles Haas,
Kaltenhouse, France) and then incubated in a humidiﬁed incubator at
38 °C on their long side. Embryos were staged accordingly to the Ham-
burger and Hamilton (HH) classiﬁcation (Hamburger and Hamilton,
1951). Eggs were windowed and HH16–17 embryos were selected for
limb-bud removal (LBR) followed by in ovo electroporation (IOE) as
previously described (La Padula et al., 2015). The empty pCIG vector,
the pCIG-HSPB3-WT or the pCIG-HSPB3-R7S plasmids (5–7 μg/μL)
were used for IOE. After electroporation, the embryos were rinsed
with sterile 0.1 M PBS pH 7.4, sealed and reincubated to reach the
sixth embryonic day (E6).
2.5. Quantiﬁcation and statistics
Isl1/2 positive cellsweremanually countedwith themulti-point tool
of ImageJ software.We counted every 10th section (25 sections average
per sample) on the electroporation sidewith or without LBR and on the
contralateral side without lesion as an internal control. Then, the per-
centage of the surviving MNs was calculated normalizing the data on
the control side. Three independent samples were quantiﬁed for every
condition. Signiﬁcance was calculated by unpaired t-test. Results are
expressed as the average percentage ± SEM.2.6. Bioinformatic analysis
The sequences of HSPB3 human, mouse and avian proteins
(NP_006299.1, NP_064344.1, XP_001231558.1) were compared by
using the multiple alignment tool of ClustalW2 (http://www.ebi.ac.uk/
Tools/msa/clustalw2/) using default settings.
For mRNA (NM_006308.2, NM_019960.2, XM_001231557.2) and
protein comparisons of the human, murine and avian HSPB3 and the
other HSPBs, the algorithms blastn/discontinuous blast and BlastP
were used with default settings.2.7. Cell culture
Neuro2A cells (Sigma-Aldrich) were cultured on 12mm round glass
coverslips placed in a 24-well plate in presence of DMEM supplemented
with 4.5% glucose, 1% penicillin/streptomycin, 1% of non-essential
amino acids (NEAA) and 10% fetal bovine serum (FBS) (all components
were purchased from Life Technologies). Cells at 60–70% of conﬂuency
were transfected with the pCIG-HSPB3-WT construct using Lipofecta-
mine (Sigma-Aldrich) following manufacturer's instructions. The day
after, the GFP signal was checked at an inverted ﬂuorescence micro-
scope (Axio Imager 2, Zeiss), and cells were ﬁxed for electron
microscopy.
HeLa cells (Sigma-Aldrich) were cultured on 6-well plates in pres-
ence of DMEM supplemented with 10% FBS and 1% penicillin/strepto-
mycin/neomycin (PSN) (Life Technologies). Like for the Neuro2A cells,
HeLa cells were transfected when the 60–70% of conﬂuency was
reached, with the empty pCIG plasmid, the pCIG-HSPB3-WT, the pCIG-
HSPB3-R7S constructs using Lipofectamine (Sigma-Aldrich) following
manufacturer's instructions (untransfected cells followed the same pro-
tocol omitting the plasmid at the plasmid incubation step). The day
after, the GFP signal was checked, and cells were harvested for the fol-
lowing protein extraction.2.8. Pre-embedding immuno-electron microscopy
The culture medium was removed from the Neuro2A cell cultures,
cells were washed 2 times with sterile 0.1 M PBS and then ﬁxed with
4% PFA plus 0.1% (ﬁnal concentration) glutaraldehyde (GA) in 0.1 M
phosphate buffer (PB) pH 7.4 for 1 h at RT. Cells were washed three
times in 0.1 M PB, washed with 50 mM Tris buffered saline (TBS), and
the epitopes blocked adding 20% normal goat serum (NGS) 1 h at RT.
Primary antibody against HSPB3 (Sigma-Aldrich) was diluted (1:50)
in 50 mM TBS with 2% NGS, added on the coverslips, and incubated
ON at 4 °C. The day after, coverslips were washed with 50 mM TBS
and the secondary biotinylated goat anti-rabbit antibody (1:100)
(Linaris Biologische Produkte GmbH) diluted in 50 mM TBS with 2%
NGS was applied on the cells and incubated ON at 4 °C. Finally, cells
were washedwith 50mM TBS, and the avidin-biotin conjugated perox-
idase complex (ABC)was applied 1 h at RT. TheDAB reactionwas devel-
oped and observed against awhite background (4min of development).
The reactionwas stoppedwith TBS and the cells werewashed in 50mM
TBS 15 min. Cells were then postﬁxed in 1% osmium tetroxide in 0.1 M
PBwith 6.85% sucrose 1 h at RT, rinsed, and serially dehydrated in grad-
ed ethanols to be embedded in Durcupan resin (Electron Microscopy
Sciences) using the ﬂat embedding conﬁguration. The same protocol
was used for silver-enhancement staining, where a secondary gold-
conjugated (8 nm) antibody was used. Ultrathin (60–70 nm) sections
were cut with a 45° diamond knife (Diatome) at a Leica ultracut EM
UC7 (Leica Microsystems) and collected on formvar-carbon-coated
nickel grids (Electron Microscopy Sciences). Images were taken with a
LEO 906E electron microscope at 100 kV using a 2K CCD camera
“sharp eye” (Tröndle).
43V. La Padula et al. / Experimental Neurology 286 (2016) 40–492.9. Post-embedding immuno-electron microscopy
The spinal cord dissected from E7 chicken embryos were ﬁxed with
4% PFA plus 0.1% (ﬁnal concentration) GA diluted in 0.1M PB pH 7.4 ON
at 4 °C. The day after, samples were rinsed several times in 0.1 M PB
pH 7.4 and then dehydratedwith an ascending ethanol scale at RT in ag-
itation, pre-impregnated in London Resin White (LRW) (Electron Mi-
croscopy Sciences) resin in a 1:1 ratio in absolute ethanol 1 h 30' at
4 °C in agitation and then impregnated in pure LRW ON at 4 °C on a
rocking plate. Finally, another step with fresh LRW was added (1 h at
4 °C on rocking plate), samples were transferred in gelatin capsules
ﬁlled with fresh LRW, let 1 h RT to settle and ﬁnally placed at 55 °C
two days for complete resin polymerization. Ultrathin (60–70 nm) sec-
tions were cut with a 45° diamond knife (Diatome) at a Leica ultracut
EM UC7 (Leica Microsystems) and collected on formvar-carbon-
coated nickel grids (Electron Microscopy Sciences). Images were taken
with a LEO 906E electron microscope at 100 kV using a 2 K CCD camera
“sharp eye” (Tröndle).
2.10. Cryo-electron microscopy and immuno-electron microscopy
The spinal cord and the sciatic nerves were dissected from a P32
mouse (a kind gift of Dr. Frick, University of Bordeaux) perfused with
4% PFA in 0.1 M PB pH 7.4 and postﬁxed in 4% PFA plus 0.2% GA (ﬁnal
concentration) ON at 4 °C. The day after, the samples were rinsed with
0.1 M PB pH 7.4, washed twice in 50 mM glycine in 0.1 M PB pH 7.4,
and then placed in 2.3 M sucrose in 0.1 M PB pH 7.4 ON at 4 °C on a
rocking plate. The samples were put on OCT compound (TissueTek,
Thermo Fisher Scientiﬁc Inc.) and cut using a cryoultramicrotome
Leica UC7-FC7 (Leica Microsystems) at −120 °C and an immuno-
diamond knife (Diatome). Ultrathin sections (60–70 nm) were
picked-up with a mixture of 2% methylcellulose/2.3 M sucrose (v/v),
collected on formvar-carbon-coated nickel grids (Electron Microscopy
Sciences) and immunostained using standard protocols. Brieﬂy, sections
were treated with 50 mM glycine for aldehyde quenching, epitopes
were blocked with 0.1 M PBS/1% BSA, incubated with the primary anti-
body anti-HSPB3 (1:70) (Sigma-Aldrich, SAB1100972), washed, and
then the reaction was revealed using a goat anti-mouse gold-
conjugated (10 nm) secondary antibody (1:50) (Aurion). Images were
taken on a TEM Hitachi H7650 at 80 kV.
2.11. Protein extraction and Dot blots
HeLa cells were harvested in 150 μL of NP40 cell lysis buffer
(Thermoﬁsher Scientiﬁc) supplemented with protease and phospha-
tase inhibitors (Sigma-Aldrich). The cells were scraped off the Petri
dish with sterile cell scrapers (Sigma Aldrich). The lysates were collect-
ed in sterile tubes and kept at−20 °C until usage.
Unﬁxed cryosections from human muscle biopsies were obtained
from the Department of Neuropathology, University of Freiburg. Isola-
tion of proteins from muscle tissue cryosections was performed using
the Qproteome FFPE Tissue Kit from Qiagen (Hilden, Germany) accord-
ing to themanufacturer's instructions. Dot blots were performed essen-
tially as described earlier (Roussa et al., 2008). 80 mg protein of HeLa
cells either non transfected (C), transfected with empty vector (P),
transfected with HSPB3 (H) or transfected with mutant HSPB3 (R),
and 20 mg of protein obtained from human muscle biopsies (M) was
loaded onto nitrocellulose membrane. The membrane was blocked
with 3% low fat milk powder in TTBS (Tris-Tween-buffered-saline)
and incubated with primary anti-HSPB3 (1:1000), anti-GFP (1:1000),
anti-GAPDH (1:10,000) or anti-Dys-1 (1:500) overnight at 4 °C. The fol-
lowing day the membrane was incubated with either anti-mouse or
anti-rabbit IgG coupled to peroxidase (1:10,000) and was developed
using the Cell Signaling SignalFire© enhanced chemiluminescence
(ECL) detection system. Signals were visualized on X-ray ﬁlm.3. Results
3.1. HSPB3 protein distribution
3.1.1. HSPB3 protein distribution in the chicken (E3–E14) andmouse (E13)
embryos
To elucidate the HSPB3 protein localization, we stained coronal spi-
nal cord sections of chicken embryos during development from the em-
bryonic developmental day three (E3) until E14, when the
developmental programmed cell death (PCD) of MNs ends (Hamburger
and Hamilton stages HH16–17 till HH40) (Hamburger and Hamilton,
1951). HSPB3 (green; Fig. 1a–i) was detectable in the radial glia (RG)
(vimentin, red; Fig. 1a–c) starting from E3 (inset in Fig. 1a, arrows)
until E12 (Fig. 1e, arrows)when its expression decreased concomitantly
with RG differentiation (McDermott et al., 2005), persisting in the re-
maining RG until E14 (not shown). Interestingly, we found the same
distribution in the RG in the spinal cord of E13 (corresponding to the
chicken embryonic day 6)mouse embryos (nestin, red; Fig. 1f), suggest-
ing a conserved distribution pattern among species. On the contrary,
MNs somata (Isl1/2, red; Fig. 1a’–c’) did not appear HSPB3-positive be-
fore E7 (Fig. 1c’, arrowheads), becoming detectable at E9 (Fig. 1d, ar-
rowheads) and being evident at E12 (Fig. 1e, arrowheads).
Interestingly, HSPB3 appeared in MN axons as early as E4
(neuroﬁlaments, red; Fig. 1g, arrows), when MNs start elongating
their axons to the periphery, and persisted in PNS axons till E14
(Fig. 1i). At E6, HSPB3 was detectable in the axons of both motor
(Fig. 1h, arrow) and sensory (Fig. 1h, arrowhead) neurons aswell. Addi-
tionally, the dermomyotome, the tissue precursor of the skeletalmuscle
(von Maltzahn et al., 2012), appeared to be strongly positive in the
chicken embryo (Fig. 1a and a’, E3, asterisks; Fig. 1g, E4, asterisk).
3.1.2. HSPB3 protein expression in postnatal chicken, mouse and human
The ﬁrst symptoms of dHMN2C due to the HSPB3-R7S mutation
begin in the second decade of a patients' life. Therefore we tested,
whether HSPB3 expression was still present in MNs postnatally, and
whether HSPB3 protein was distributed in the PNS as well. For this,
we compared both longitudinally cut peripheral nerves (Fig. 2a–c)
and transversally cut spinal cords (Fig. 2d–f) from different vertebrates,
namely adult chicken (Fig. 2a and d), mouse (Fig. 2b and e), and human
(Fig. 2c and f). One of the more interesting features we found was that
HSPB3 protein is localized in the axons of both PNS motor (Fig. 2a and
b, arrows, chicken and mouse sciatic nerves) and PNS sensory (Fig. 2c,
arrows, human sural nerve biopsy) neurons. Indeed, it is well known
that other HSPB members, such as HSPB1, HSPB5 and HSPB8, interact
with cytoskeletal proteins. It has been demonstrated that HSPB1 plays
a role in the regulation of axonal transport by decreasing tubulin acety-
lation and consequently causing the destabilization of the microtubule
network (d'Ydewalle et al., 2011). Several HSPB1 mutations causing
CMT2F/dHMN2B have been identiﬁed (see Datskevich et al., 2012 for
a review). Similarly, HSPB8 mutations have the same inﬂuence on the
axonal stability but the way HSPB8 interacts with the microtubules is
still not known. Presumably, this could happen through its association
with HSPB1 (Fontaine et al., 2005). Regarding HSPB5, mutations of
this protein can cause myoﬁbrillary myopathy (Sacconi et al., 2012)
and it has been demonstrated that HSPB5 acts as a chaperone for actin
and desmin (Perng et al., 1999).
In the spinal cord, HSPB3 was found perinuclearly in MNs
(Fig. 2d–f, arrows) as well as in glial cell cytoplasm (Fig. 2d–f, arrow-
heads). Localization of HSPB3 in the motor and sensory systems was
further conﬁrmed by staining in the axons of both the ventral and
dorsal roots of the mouse spinal cord (Fig. 2g and h, arrows) and in
dorsal root ganglia (DRG) somata (Fig. 2l, arrowhead). The distribu-
tion in DRGs was already present in E14 chicken embryos (Fig. 2i,
arrowhead).
Taken together, our data conﬁrmed the presence of HSPB3 pro-
tein in both motor and sensory neurons, which suggests a putative
Fig. 1. HSPB3 protein distribution during chicken embryonic development and in E13 mouse embryos: (a–i) HSPB3 protein (green) is expressed throughout the chicken embryonic
development, from embryonic day 3 (E3, a and a’) till E14 (i). (a–e) From E3 (a, arrows) till E12 (e, arrowhead) HSPB3 is expressed in radial glia (RG) (vimentin, red; a–c and inset in
a, arrows). (g–i) HSPB3 is also localized in the axons (neuroﬁlament, red) of motor (g and h, arrows; E4 and E6) and sensory (h, arrowhead; E6) neurons and later in the axons of
peripheral nerves (i, E14). (a, a’ and g) The dermomyotome clearly express HSPB3 (asterisks; E3 and E4). (a’–c’, d and e) Cell bodies of MNs (red, Isl1/2) start being positive for HSPB3
protein from E9 (d, arrowheads) till E12 (e, arrowheads). (f) In mouse embryos (E13), HSPB3 is expressed in RG (nestin, red) as well. Scale bars: a-a’ and d–f (20× magniﬁcation),
100 μm; b–b’, c–c’, i (63× magniﬁcation) and g–h (40× magniﬁcation), 25 μm.
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in the motor neuropathy with a mild sensory loss as described in
those patients carrying the R7S mutation of HSPB3 (Kolb et al.,
2010).Fig. 2.HSPB3protein distribution in spinal cord and peripheral nerve of postnatal chicken,mous
in the glial cytoplasm(arrowheads), and (a–c) in the axons of peripheral nerves (arrows) in adu
axons of both the ventral (h) and dorsal (g) roots of spinal cord and in the dorsal root ganglia (D
at E14. Scale bars: a–c, g, h, 20 μm; d–f, i, l, 50 μm.3.1.3. Subcellular distribution of HSPB3
Having determined the cell-type speciﬁc distribution of HSPB3, we
next sought to elucidate its subcellular localization by immuno-
electron microscopy (IEM) both in vitro and in vivo. A pre-embeddinge andhuman: (d–f) Postnatally, HSPB3 localizes perinuclearly in spinal cordMNs (arrows),
lt chicken (a and d),mouse (b ande), and human (c and f). (g–h and l) It can be found in the
RG) (l) of the adult mouse. (i) Its expression is already present in the chicken embryoDRG
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blastoma cell line) detected endogenous HSPB3 protein in various
cellular compartments, such as the cytoplasm (Fig. 3a–d, asterisks),
actin ﬁlaments (Fig. 3a–c, arrows), the outer mitochondrial membrane
(OMM) (Fig. 3a, c and d, black arrowheads) and to some extent inmito-
chondrial cristae (Fig. 3d, white arrowhead). Since the scarce localiza-
tion in the cristae could be attributed to the limitations of the pre-
embedding IEM, we employedmore sensitive post-embedding labeling
procedures for the following experiments.
We stained coronal sections of spinal cords from postnatal mice
(P32, Fig. 3e and f) and chicken embryos (E7, Fig. 3 h) as well as longi-
tudinal sections of the murine sciatic nerve (Fig. 3g) to investigate the
ultrastructural expression of HSPB3 in the CNS and the PNS. We found
that HSPB3 has a similar distribution in vivo and in vitro, being present
in MN cytoplasm (Fig. 3f, asterisk), and in neuroﬁlaments in the axons
of both central (Fig. 3e,f,h and inset in Fig. 3h, arrows) and peripheral
(Fig. 3g, arrows) nervous systems. At the mitochondrial level, HSPB3
positivity is not only restricted to theOMM(Fig. 3e,g andh, black arrow-
heads) and cristae (Fig. 3e,g and h, white arrowheads), but is also found
in the inner mitochondrial membrane (IMM) (Fig. 3e and f, dark grey
arrowheads). Of note, the cytoplasmic and cytoskeletal distribution of
HSPB3 was visible by all microscopy methods (Fig. 1d–e and g–i;
Fig. 2), whereas the mitochondrial localization was only detectable
due to the higher sensitivity of the electron microscopy.
3.2. Overexpression of HSPB3-WT and HSPB3-R7S in the chicken embryo
subjected or not to limb-bud removal
To evaluate the roles of WT HSPB3 and of its R7S mutated form on
MNs survival, we cloned the chicken HSPB3 gene (WT or R7S) in a
pCIG (pCAGGS-IRES2-nucEGFP) overexpression vector (Megason and
McMahon, 2002) (Supplementary Fig. 1c) using an empty pCIG vector
as an internal control. Plasmids were transferred into the neural tube
of E3 chicken embryos (Supplementary Fig. 1d-1 and d-2) by in ovo
electroporation (IOE) using a diagonal conﬁguration of the electrodes
to better target the MN progenitors, as previously described (La
Padula et al., 2015) (Supplementary Fig. 1d-3). Transfected embryos
were sacriﬁced three days later - at E6 - before the start of the develop-
mental PCD period at E6.5–E7. Quantifying the effect of WT andFig. 3. Subcellular distribution of HSPB3 protein in vitro and in vivo: (a–d) In vitro, on Neuro2
localized in actin ﬁlament bundles (a–c, arrows) and at the level of the outer mitochondrial
similar distribution in vivo, in postnatal (P32) mouse (spinal cord, e–f; sciatic nerve, g) and c
black arrowheads) and inner (e and f, dark grey arrowheads) membranes and in cristae (e,
peripheral (g) nervous systems (arrows). Magniﬁcation: a, c, d, 10K; b, 16.7K; e, 70K; f, 100K;mutated HSPB3 at E6 was important, since PCD not only reduces the
number of MNs but also modiﬁes their gene expression. To compare
the effect of HSPB3-WT and R7S on healthy and on dying MNs, we
established two experimental conditions: the ﬁrst consisted in
electroporating the spinal MNs by IOE on normal embryos and the sec-
ond involved an additional LBR (schematized in Supplementary Fig. 1d-
4 and d-5 and in Fig. 4d and h).
3.2.1. Effects of the overexpressed HSPB3-WT and HSPB3-R7S on healthy
and degenerating MNs
Overexpression of HSPB3-WT (Fig. 4b) signiﬁcantly reduced the
number of MNs in normal (without LBR) conditions compared to con-
trol (pCIG empty vector; Fig. 4a) (reduction of 20.53%: pCIG 92.03% ±
2.9 vs.WT 71.5% ± 1.4; p = 0.0016, Fig. 4d), whereas in conditions of
cell degeneration with LBR HSPB3-WT (Fig. 4f) rescued a signiﬁcant
number of dying MNs compared to the pCIG control (Fig. 4e) (increase
by 43.5%: pCIG 41.6%±15 vs.WT85.2%±2.4; p=0.025, Fig. 4h). Over-
expression of HSPB3-R7S showed a higher variability in inducing MN
survival or death compared to HSPB3-WT. Indeed, HSPB3-R7S
(Fig. 4g) did not show a signiﬁcant difference in the rescue of MNs
after lesion compared to control (Fig. 4e) (increase by 35.9%: pCIG
41.6% ± 15 vs. R7S 77.6% ± 13.4; p = 0.094, Fig. 4h), although there
was a mild trend in increased MN survival. On the contrary, HSPB3-
R7S overexpression without lesion (Fig. 4c) had a pronounced effect
on MN death compared to control (Fig. 4a) (decrease by 35.8%: pCIG
92.03% ± 2.9 vs. R7S 56.18% ± 9.1; p = 0.01, Fig. 4d). Importantly,
there was no signiﬁcant difference between the effects obtained by
HSPB3-WT and HSPB3-R7S in both conditions (without LBR, difference
by 15.31%, p= 0.11; with LBR, difference of 7.6%, p= 0.53).
Taken together, these results strongly indicate that HSPB3-WT and
its mutation R7S share common properties on MNs survival and
death, and that such properties depend on the cellular state.
4. Discussion
The family of small heat shock proteins (HSPBs) represents an im-
portant group of ubiquitous proteins involved in key processes of the
cellular physiology, such as cell survival, cytoskeletal remodeling, and
protein degradation. In humans, 10 members (HSPB1–10) have beenA cells, HSPB3 protein is diffusely distributed in the cytoplasm (a–d, asterisks). It is also
membrane (a, c, d, black arrowheads) and cristae (d, white arrow). (e–h) HSPB3 has a
hicken embryo (E7) (spinal cord, h), being expressed in mitochondrial outer (e, g and h,
g and h, white arrowheads), and neuroﬁlaments in both central (e, f, h, inset in h) and
g, 80K; h, 13K; inset in h, 16.7K Scale bars a–d, h and inset in h 250 nm; e–g, 200 nm.
Fig. 4. The overexpression of HSPB3 inboth itsWT andmutated form inducesmotoneuron reduction or recovery depending on the cellular conditions: (a–d) the overexpression ofHSPB3-
WT (green; b) or of itsmutated formR7S (green; c) causes a signiﬁcant decrease (d) ofMN (Isl1/2, red; a–c) number in E6 chicken embryoswithout limb-bud removal (LBR), whereas the
overexpression of the empty plasmidpCIG (green; a)doesnot induce any change in theMNpopulation number. (e–h)On the contrary, the overexpression ofHSPB3-WT (green; f) induces
a signiﬁcantMN (Isl1/2, red; e–g) survival in E6 chicken embryos undergoing lesion-induced cell death due to LBR (h) while HSPB3-R7S overexpression (green; g) displays a tendency in
the rescue, albeit not signiﬁcant (h). The overexpression of the pCIG plasmid alone (e, green) does not cause anyMN rescue and does not interfere with the cell death induced by the LBR.
The schemas in d and h represent the experimental conditions. n= 3 from three independent experiments. Columns represent mean ± SEM. Scale bar, 50 μm.
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pathologies. Notably, three of them (HSPB1, HSPB3, and HSPB8) cause
motor neuropathies.
In this work, we studied the distribution of HSPB3 in the nervous
systemof chicken,mouse and human by light, confocal and electronmi-
croscopy. We investigated its function on avian motoneuron (MN) sur-
vival using a paradigm of lesion-induced cell death (the limb-bud
removal, LBR) (Oppenheim et al., 1978) combinedwith the electropora-
tion in ovo (IOE) of HSPB3 wild type (WT) or of its mutation R7S on the
developing chicken embryo. The two goals of ourwork consisted ﬁrst in
acquiring a better understanding on the localization of the endogenous
HSPB3 and, second, in knowing the function and effects of HSPB3-WT
and of its pathogenic mutated form (HSPB3-R7S) - which is known to
cause a genetic peripheral neuropathy classiﬁed as dHMN2C (Kolb
et al., 2010) - on healthy and degenerating MNs.
Structurally, HSPBs are characterized by the presence of an alpha-
crystallin domain, the target of many of the mutations causing human
diseases. Nonetheless, mutations involving the N′- or the C′-terminal
domains of HSPBs are disease causing in humans. Among them is the
R7S mutation that is located on the N′-terminal of the HSPB3 protein.
Four different mutations have been documented on this domain in
HSPB1, all causing distal hereditary motor neuropathies (Datskevich
et al., 2012).
In thiswork,we showed for theﬁrst time the embryonic and postna-
tal localization of the HSPB3 protein in the central and peripheral ner-
vous systems, ﬁnding it localized in the cytoplasm of glial cells as well
as in the cell bodies and axons of motor and sensory neurons. Interest-
ingly, HSPB3 localization in MNs changed over time, appearing diffused
in the somata in late avian embryonic stages (not detectable until E9)
and perinuclear postnatally (in all the species examined). We think
that this shift is due to the different molecular processes occurring in
MNs during development. Indeed, HSPB3 somatic localization appeared
to be detectable by confocal microscopy only at E9 and much more atE12, when the developmental programmed cell death was reaching its
end. The perinuclear distribution has been documented also in MNs of
postnatal transgenic mice overexpressing the human HSPB1 (Sharp
et al., 2006).
At the ultrastructural level, HSPB3 is widely distributed within the
cell. Indeed, we found it located in the cytosol, associated to the outer
and innermitochondrialmembranes (OMM and IMM), tomitochondri-
al cristae and also to actin bundles and neuroﬁlaments in vitro and
in vivo. These data are particularly interesting, because both mitochon-
drial and neuroﬁlament dysfunctions are at the base of several types
of peripheral neuropathies, such as CMT2E/1F (neuroﬁlament light
chain, NF-L) (Fabrizi et al., 2007), CMT2A (mitofusin, MFN2) (Stuppia
et al., 2015) and CMT4A (ganglioside-induced differentiation-
associated protein 1, GDAP1) (Niemann et al., 2005).
The translocation to themitochondria has been shown for the phos-
phorylated form of HSPB5 inmouse retina under stress conditions using
biochemical methods conﬁrming its localization at mitochondrial cris-
tae by immuno-electronmicroscopy (IEM) (Chis et al., 2012). Nonethe-
less, Nakagawa and colleagues showed by biochemical and
immunolocalization studies that HSPB2 is loosely associated with the
OMM (Nakagawa et al., 2001). Using a similar approach, Morrow and
colleagues (Morrow et al., 2000), showed that the Drosophila
melanogaster ortholog of HSPB8 (DmHsp22) is located in themitochon-
drial matrix. The same group (Morrow et al., 2004), demonstrated that
both the ubiquitous or MN-restricted overexpression of DmHsp22 ex-
tends the Drosophila life span and that the MN overexpression results
in the maintenance of a normal locomotion pattern and in a higher re-
sistance of MNs to oxidative stress. A shift to a mitochondrial localiza-
tion has also been documented in vitro for HSPB1 on butyrate-treated
IEC-18 cells, an intestinal crypt cell line (Parhar et al., 2006). In the
light of these ﬁndings we propose that HSPB3 - similar to HSPB2,
HSPB5, andHSPB1- is a cytoplasmic protein able to dynamically translo-
cate to mitochondria, where it putatively interacts with proteins
47V. La Padula et al. / Experimental Neurology 286 (2016) 40–49involved in cellular survival or death. Here, we showed the cytoskeletal
localization of HSPB3 that is a feature shared with other small heat
shock proteins (such as HSPB1 and HSPB5; Miron et al., 1991; Perng
et al., 1999), which suggests that HSPB3 could play a role in cytoskeletal
dynamics regulation as well. Indeed, it has been demonstrated that
point mutations affecting HSPB1 and HSPB5 lead to axonal CMT and
myoﬁbrillary myopathy (Houlden et al., 2008; Sacconi et al., 2012)
and that HSPB1 acts as a negative regulator of actin polymerization
(Miron et al., 1991). Our ﬁnding justiﬁes the axonal length-dependent
motor neuropathy caused by the HSPB3-R7S point mutation in the af-
fected subjects.
Finally, we studied the functional properties of HSPB3 on healthy
and dying MNs, demonstrating that both the WT and the mutated
HSPB3 proteins play a similar role on MNs survival and death. We
overexpressed by IOE HSPB3-WT or its pathogenic mutation R7S in
dyingMNs of embryos presenting LBR. The quantiﬁcation of the surviv-
ing MNs three days after the induction of degeneration showed that
both HSPB3-WT and R7Swere able to rescueMNs from cell death, albeit
the latter lessmarkedly than the former, and that they induced a similar
cell loss when overexpressed in healthy MNs (without LBR). Based on
our results, we conclude that HSPB3 plays a role in spinal MNs survival,
when the apoptotic machinery is activated in both its WT and mutated
form.
Many HSPBs - such as HSPB1, HSPB2, and HSPB8 - play a role on cell
survival, directly acting on the main actors involved in cell death. Nota-
bly, the overexpression of HSPB1 following nerve crush in rats is able to
rescue MNs from cell death (Benn et al., 2002). Indeed, the anti-
apoptotic function of HSPB1 has been well documented, identifying its
function as a negative modulator of apoptosis (Charette and Landry,
2000; Paul et al., 2010). Interestingly, a recent study on MDA-MB-231,
a human breast cancer cell line, has identiﬁed the anti-apoptotic proper-
ties of HSPB2, inhibiting caspase-2 activation and Bid cleavage (Oshita
et al., 2010). A wider effect on cell survival is exerted by HSPB8, which
plays a role on both survival and apoptosis (Aurelian et al., 2012;
Modem et al., 2011; Sharma et al., 2006; Smith et al., 2011) (see
Table 1b for the function of HSPBs on cell death). We found such a
dual role for HSPB3 as well. It is protective when overexpressed in
degenerating MNs and inducing cellular loss if overexpressed in
steady-state MNs, which is akin to the behavior of HSPB8. Given these
facts together with our data we propose that HSPB3 exerts its function
in the spinal cord preferentially by interacting with the more abundant
HSPB8 rather thanwith HSPB2 (the low expression of HSPB2mRNAhas
been shown in spinal cord MNs by the Allen Spinal Cord Atlas, http://
mousespinal.brain-map.org/). For this reason, HSPB3 could putatively
act as a cell death inhibitor or inductor according to the cellular back-
ground of gene expression in spinal cord MNs.Table 1
a. Relevant protein-protein interactions (PPI) performed by HSPB proteins. b. Activity of HSPB
a.
Interactor HIPPIE PPI Methods used to establish PP
HSPB3 HSPB2 0.80 Afﬁnity chromathography, afﬁ
HSPB8 0.63 Two-hybrid screening
NF-L 0.63 Two-hybrid screening
HSPB8 HSPB1 0.96 FRET, afﬁnity capture-western
HSPB2 0.88 FRET, afﬁnity capture-western
b.
Action on apoptosis Way of action
HSPB1 Inhibition Inhibition of: Cyt C, casp3, Daxx
HSPB2 Inhibition Inhibition of: casp2, Bid cleavage
HSPB8 Inhibition Prevention or reduction of partial
Induction Interaction with protein kinases (
HSPB3 Inhibition Not known
Induction Not knownVery little is known about HSPB3 interaction partners. Notably,
HSPB3 interaction with HSPB2 has been documented as important for
the muscular development (Sugiyama et al., 2000), whereas the effect
of its relation with HSPB8 is not known (Fontaine et al., 2005). It is im-
portant to note that HSPB8 interacts with HSPB1 and HSPB2 (Sun et al.,
2004) (Table 1a) and that HSPB1 and HSPB8 proteins are expressed in
MNs cell bodies (Crippa et al., 2010; Sharp et al., 2006). Therefore, we
assume that a functional redundancy among the HSPBs would justify
the low severity and the slow progression of the dHMN2C caused by
the R7Smutation inHSPB3 alone.We also evaluated the interactions oc-
curring among HSPBs and other relevant proteins by using the Human
Integrated Protein-Protein Interaction rEference (HIPPIE), a database
that applies a speciﬁc algorithm to assign a rate of protein-protein inter-
action (PPI) based on the quantity and the quality of scientiﬁc evidence
for a given interaction (Schaefer et al., 2012) (Table 1a). All these inter-
actions are considered of high conﬁdence (conﬁdence score N 0.73). Yet
the PPI between HSPB3 and HSPB8 obtained a conﬁdence score of 0.63,
having been demonstrated by a high-throughput yeast two-hybrid
technique alone (Table 1a) butwe believe, based on our results, that fur-
ther studies could conﬁrm such interaction. Additionally, the interaction
betweenHSPB3 and neuroﬁlament light chain (NF-L)was shown by au-
tomated yeast two-hybrid analysis (score 0.63; Stelzl et al., 2005). This,
asmentioned before, is conﬁrmed by our IEM analysis. Moreover,muta-
tions of the gene coding for NF-L induces cytoskeletal disorganization,
causing an axonal form of CMT (CMT2E; Fabrizi et al., 2007).
Peripheral neuropathy in humans is caused by a heterozygousmuta-
tion in HSPB3. The symptoms start around the second life decade and
the disease develops progressively over years, indicating a slowMNde-
generation. In combination with our ﬁndings this suggests that the
human HSPB3-R7S presents a gain-of-function, compensated in part
by the presence of the endogenous HSPB3-WT protein in MNs. Based
on the similar behavior between the WT and the mutated R7S protein,
one could conclude that the mutated protein has no pathogenic effect.
We think this is not the case andwe believe that long-term in vivo stud-
ies in mouse are needed to provide necessary information on the func-
tion of this protein - in itsWT andmutated forms -, whichwe showed to
be important for MNs physiology. Indeed, our experimental conditions
were not designed to extend the time window of HSPB3 overexpres-
sion, due to the fact that the ontogenetic programmed cell death taking
place in MNs occurring in the embryo starting at E6.5–E7 would have
reduced the MN population and modiﬁed their genetic background.
Consequently, this wouldn't have allowed us evaluating the effects of
HSPB3-WT and R7S on cell survival of MNs undergoing induced cell
death in the living chicken embryo, the second aim of our study.
Whether the interaction of theHSPB3-R7S proteinwith its partners -
like HSPB8, HSPB2, mitochondrial or neuroﬁlament proteins - differsproteins on cell survival.
I Reference
nity capture-western, in vivo Sugiyama et al., 2000
Fontaine et al., 2005
Stelzl et al., 2005
, afﬁnity chromathography, in vitro Fontaine et al., 2005
, afﬁnity chromathography, coimmunoprecipitation Fontaine et al., 2005
Reference
Benn et al., 2002
Charette and Landry, 2000
Oshita et al., 2010
ly unfolded proteins Chavez Zobel et al., 2003
e.g. ERK1/2); Bag3 interaction Shemetov et al., 2011; Carra et al., 2008
Data presented in our work
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portant to investigate.
Gain-of-function mutations have been documented for other pro-
teins involved in the pathogenesis of peripheral neuropathies, leading
to both axonal and demyelinating CMT (Grandis et al., 2008; Motley
et al., 2011; Sowa et al., 2014).
In summary, ourwork shows that HSPB3protein is distributed in the
central and peripheral nervous systems, and that its overexpression in
MNs undergoing cell death is able to rescue them from apoptosis, indi-
cating its potential role as a modulator of MN survival. In addition, its
pathogenic mutation R7S behaves in a similar way than theWT protein,
suggesting a non-deleterious effect on the protein function but rather a
modiﬁcation of its behavior on the long-term, maybe by inducing the
formation of protein aggregates and a following unfolded protein re-
sponse in the spinal MNs, as shown in the case of HSPB1 (Ylikallio
et al., 2015).
5. Conclusions
Taken together, our data justify the symptoms and the progression
of the human pathology documented for the mutated HSPB3 protein,
and open new perspectives for the study of therapeutic approaches.
Regarding long-term studies to performonmice, it is actually impor-
tant to note that knock-outmice for HSPB1 andHSPB5 do notmimic the
phenotype of the pathology (Brady et al., 2001; Huang et al., 2007), but
only transgenic mice carrying the pathogenic mutations do (Andley
et al., 2011; Lee et al., 2015). For this reason, we think that the creation
of a transgenic mouse carrying the HSPB3-R7S gene could better con-
tribute to the understanding of the cellular and molecular mechanisms
leading to the dHMN2C caused by the R7S mutation of HSPB3. In addi-
tion, such a model would allow therapeutic interventions for which
we envision various different approaches: the ﬁrst would be the selec-
tive inhibition of the mutated protein by RNA interference (RNAi), as
it has already been successfully done in vivo in a mouse model of amyo-
trophic lateral sclerosis (Xia et al., 2006). The second would consist in
the overexpression of the WT protein, in an attempt to rescue MNs
from degeneration. And, lastly, one could combine these two strategies
to improve the chances of rescuing MNs from an early degenerative
state.
Another gene therapy option could be the overexpression of other
HSPBs, direct or indirect interactors of HSPB3. This idea has been recent-
ly proven to be effective in vitro in the case of three HSPB5 pathogenic
mutations (Hussein et al., 2015).
Alternatively, a pharmaceutical approach could be explored, like the
inhibition via speciﬁc drugs of deacetylating enzymes, whose efﬁcacy
was demonstrated in vivo on mice carrying two different mutations of
HSPB1 that induced CMT2F and dHMN2B; in these mice, the inhibition
of the histone deacetylase 6 (HDAC6) enzyme rescued their phenotype
(d'Ydewalle et al., 2011). Despite all these initial insights, an in depth
understanding of the molecular pathways around HSPB3 will be neces-
sary for a successful in vivo therapy in humans.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.expneurol.2016.08.014.
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